An observational study in Chronic Lymphocytic Leukaemia (CLL), sponsored by AstraZeneca. Active, not recruiting at 61 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Leukemia, B-Cell with a site in Germany — 7 open to participants now, 11 under way, 3 of them phase 3. Leukemia, B-Cell · Germany.
Among the 21 studies in Leukemia, B-Cell with a site in Germany, this one is one of 2 that started in 2022, is one of 4 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.
191 studies on the registry are indexed under Leukemia, B-Cell; 53 are open to participants now.
Browse Leukemia, B-Cell studies →7 of the 21 studies in Leukemia, B-Cell with a site in Germany are open now. Recruiting first, the newest first:
Medical University Innsbruck · Sites in Germany, Austria
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 10 more countries
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 7 more countries
Ages 18+
Technical University of Munich · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Japan and 1 more country
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 40 Leukemia, B-Cell studies recruiting now, 19 (48%) set no upper age limit and 16 (40%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 5
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 193 is above the median of 120 across 22 observational studies indexed under Leukemia, B-Cell.
Median enrollment 66 across the 17 interventional studies, 85 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
AstraZeneca has 9 studies filed under Leukemia, B-Cell — fewer than ten, so there is no comparison to draw.
5 of the studies in Leukemia, B-Cell with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT04608318Phase 3German CLL Study GroupIbrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | 2027-09 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT04515238German CLL Study GroupSequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | 2027-02 |
| NCT05645172AstraZenecaRetention Rate of Acalabrutinib in a Non-interventional Setting | 2027-04-15 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies in Leukemia, B-Cell with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.
This observational study will prospectively assess acalabrutinib therapy retention of CLL patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. Furthermore, therapy adherence, treatment efficacy, overall survival, and QoL to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. Finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, QoL, and psychological segmentation.
CLL patients with a newly initiated acalabrutinib treatment in routine clinical practice are planned to be included from approximately 75 sites in Germany over a recruitment period of 16 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy.
Retention rate of CLL
The primary outcome of this study is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 1 year (= ratio of the number of patients still being prescribed acalabrutinib after 1 year to the number of patients at risk). Cases of death, ongoing treatment interruption, and lost to follow-up will be counted as patients not still being prescribed with acalabrutinib.
Time frame: 1 year
Retention rate of CLL
The secondary outcome is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 2 years.
Time frame: 2 years
General treatment adherence
General treatment adherence will be assessed over the whole observational period by the self-reported, 8-item structured MMAS-8 questionnaire.
Time frame: assessed at baseline and 6, 12, and 24 months after start of acalabrutinib treatment
reasons for and duration of therapy interruptions
Based on acalabrutinib treatment details, the reasons for and duration of therapy interruptions will be calculated and analysed.
Time frame: time from first prescription until therapy interruptions; assessed up to 40 months
TTD
Based on acalabrutinib treatment details, the TTD, defined as the time from first prescription until the date of last intake or death, whichever occurs first, will be calculated and the reasons for therapy discontinuation will be analysed.
Time frame: time from start of acalabrutinib treatment until the date of final discontinuation or death; assessed up to 40 months.
TTNT
Based on acalabrutinib treatment details, the TTNT, defined as the time of first prescription until start date of the next CLL treatment will be calculated and the reasons for switch of treatment will be analysed. Cases of death will be censored and not considered as TTNT-relevant event.
Time frame: time from start of acalabrutinib treatment until start of a subsequent CLL treatment; assessed up to 40 months.
TTNT-D
Based on acalabrutinib treatment details, the TTNT-D, defined as the time of first prescription until start date of the next CLL treatment or death, whichever occurs first, will be calculated.
Time frame: time from start of acalabrutinib treatment until start of a subsequent CLL treatment or death; assessed up to 40 months
Treatment efficacy and PFS
Treatment efficacy will be analysed by means of the overall treatment response (CR, PR, PRL, judged by the treating physician and recommended to be in accordance with the guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), modified for persistent lymphocytosis, the time to and duration of response, the percentage of patients without treatment response (SD, PD), as well as the time of PFS, defined as the time of first prescription until progression of the disease or death by any cause, whichever occurs first.
Time frame: time from start of acalabrutinib treatment until disease progression or death by any cause, whichever occurs first; assessed up to 40 months.
Overall survival
Overall survival will be calculated as the time from first prescription until death by any cause.
Time frame: time from start of acalabrutinib treatment until death by any cause; assessed up to 40 months.
Patient- and disease-specific factors possibly affecting the retention rate
Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Treatment effectiveness (treatment response, PFS)
Time frame: up to 40 months
Healths-related Quality of Life (HRQoL)-QLQ-C30
The QoL, as measured by the self-reported QLQ-C30 questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated. Clinical significance will be defined as minimal important differences (MIDs) of at least 10 points (in either direction) for total scores or subscales of the QLQ-C30.
Time frame: Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months
Healths-related Quality of Life (HRQoL)-EQ-5D-5L
The QoL, as measured by the self-reported EQ-5D-5L questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated.
Time frame: Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months
Patient- and disease-specific factors possibly affecting the retention rate
Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Patient- and disease-specific characteristics (sociodemographic data, disease characteristics and severity, comorbidities (CIRS), comedication).
Time frame: up to 40 months
Patient- and disease-specific factors possibly affecting the retention rate
Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Treatment adherence (MMAS-8).
Time frame: up to 40 months
Patient- and disease-specific factors possibly affecting the retention rate (Psychological patient segmentation)
Psychological patient segmentation as determinant for the disease acceptance and disease control will be performed during the baseline visit by using a questionnaire published by Bloem et al. in 2020
Time frame: at Baseline
Patient- and disease-specific factors possibly affecting the retention rate
Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Safety (rate, severity, and duration of SAEs and ADRs)
Time frame: up to 40 months
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.